STOCK TITAN
  1. Home
  2. Sec-filings
  3. ENTX
  4. [8-K] Entera Bio Ltd. Reports Material Event

[8-K] Entera Bio Ltd. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock ENTX logo
Entera Bio Ltd

NASDAQ:ENTX

ENTX Rankings

#7129 Ranked by Market Cap
N/A Ranked by Dividends

ENTX Latest News

Jul 8, 2025
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress
Jun 26, 2025
Entera Bio Data for EB613 Effects on Trabecular and Cortical Bone in Post-Menopausal Women with Osteoporosis Selected for Oral Presentation at ASBMR 2025 Annual Meeting
Jun 25, 2025
OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting
May 9, 2025
Entera Bio Announces First Quarter 2025 Financial Results and Business Updates
Apr 15, 2025
Entera Bio’s EB613 Demonstrates Early Impact on Both Trabecular and Cortical Bone Compartments with 6 Months of Treatment in Post-Menopausal Women with Osteoporosis - Highlighted as Oral Presentation at WCO-IOF ESCEO

ENTX Latest SEC Filings

Jul 18, 2025
[Form 4] Entera Bio Ltd. Insider Trading Activity
Jul 18, 2025
[Form 4] Entera Bio Ltd. Insider Trading Activity
Jul 18, 2025
[Form 4] Entera Bio Ltd. Insider Trading Activity

ENTX Stock Data

83.63M
34.56M
16.88%
24.47%
0.27%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
Israel
JERUSALEM